Cargando…
Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival
BACKGROUND: Histone deacetylases (HDACs) have been associated with malignant tumor development and progression in humans. HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical trials. The present study aimed to evaluate the clinical significance of HDAC-1, −2, −4 an...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621854/ https://www.ncbi.nlm.nih.gov/pubmed/26502922 http://dx.doi.org/10.1186/s12876-015-0379-y |
_version_ | 1782397505204387840 |
---|---|
author | Giaginis, Constantinos Damaskos, Christos Koutsounas, Ioannis Zizi-Serbetzoglou, Adamantia Tsoukalas, Nicolaos Patsouris, Efstratios Kouraklis, Gregorios Theocharis, Stamatios |
author_facet | Giaginis, Constantinos Damaskos, Christos Koutsounas, Ioannis Zizi-Serbetzoglou, Adamantia Tsoukalas, Nicolaos Patsouris, Efstratios Kouraklis, Gregorios Theocharis, Stamatios |
author_sort | Giaginis, Constantinos |
collection | PubMed |
description | BACKGROUND: Histone deacetylases (HDACs) have been associated with malignant tumor development and progression in humans. HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical trials. The present study aimed to evaluate the clinical significance of HDAC-1, −2, −4 and −6 protein expression in pancreatic adenocarcinoma. METHODS: HDAC-1, −2, −4 and −6 protein expression was assessed immunohistochemically on 70 pancreatic adenocarcinoma tissue specimens and was statistically analyzed with clinicopathological characteristics and patients’ survival. RESULTS: Enhanced HDAC-1 expression was significantly associated with increased tumor proliferative capacity (p = 0.0238) and borderline with the absence of lymph node metastases (p = 0.0632). Elevated HDAC-4 expression was significantly associated with the absence of organ metastases (p = 0.0453) and borderline with the absence of lymph node metastases (p = 0.0571) and tumor proliferative capacity (p = 0.0576). Enhanced HDAC-6 expression was significantly associated with earlier histopathological stage (p = 0.0115) and borderline with smaller tumor size (p = 0.0864). Pancreatic adenocarcinoma patients with enhanced HDAC-1 and −6 expression showed significantly longer survival times compared to those with low expression (p = 0.0022 and p = 0.0113, respectively), while a borderline association concerning HDAC-2 expression was noted (p = 0.0634). CONCLUSIONS: The present study suggested that HDACs may be implicated in pancreatic malignant disease progression, being considered of clinical utility with potential use as therapeutic targets. |
format | Online Article Text |
id | pubmed-4621854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46218542015-10-28 Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival Giaginis, Constantinos Damaskos, Christos Koutsounas, Ioannis Zizi-Serbetzoglou, Adamantia Tsoukalas, Nicolaos Patsouris, Efstratios Kouraklis, Gregorios Theocharis, Stamatios BMC Gastroenterol Research Article BACKGROUND: Histone deacetylases (HDACs) have been associated with malignant tumor development and progression in humans. HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical trials. The present study aimed to evaluate the clinical significance of HDAC-1, −2, −4 and −6 protein expression in pancreatic adenocarcinoma. METHODS: HDAC-1, −2, −4 and −6 protein expression was assessed immunohistochemically on 70 pancreatic adenocarcinoma tissue specimens and was statistically analyzed with clinicopathological characteristics and patients’ survival. RESULTS: Enhanced HDAC-1 expression was significantly associated with increased tumor proliferative capacity (p = 0.0238) and borderline with the absence of lymph node metastases (p = 0.0632). Elevated HDAC-4 expression was significantly associated with the absence of organ metastases (p = 0.0453) and borderline with the absence of lymph node metastases (p = 0.0571) and tumor proliferative capacity (p = 0.0576). Enhanced HDAC-6 expression was significantly associated with earlier histopathological stage (p = 0.0115) and borderline with smaller tumor size (p = 0.0864). Pancreatic adenocarcinoma patients with enhanced HDAC-1 and −6 expression showed significantly longer survival times compared to those with low expression (p = 0.0022 and p = 0.0113, respectively), while a borderline association concerning HDAC-2 expression was noted (p = 0.0634). CONCLUSIONS: The present study suggested that HDACs may be implicated in pancreatic malignant disease progression, being considered of clinical utility with potential use as therapeutic targets. BioMed Central 2015-10-26 /pmc/articles/PMC4621854/ /pubmed/26502922 http://dx.doi.org/10.1186/s12876-015-0379-y Text en © Giaginis et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Giaginis, Constantinos Damaskos, Christos Koutsounas, Ioannis Zizi-Serbetzoglou, Adamantia Tsoukalas, Nicolaos Patsouris, Efstratios Kouraklis, Gregorios Theocharis, Stamatios Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival |
title | Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival |
title_full | Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival |
title_fullStr | Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival |
title_full_unstemmed | Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival |
title_short | Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival |
title_sort | histone deacetylase (hdac)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621854/ https://www.ncbi.nlm.nih.gov/pubmed/26502922 http://dx.doi.org/10.1186/s12876-015-0379-y |
work_keys_str_mv | AT giaginisconstantinos histonedeacetylasehdac124and6expressioninhumanpancreaticadenocarcinomaassociationswithclinicopathologicalparameterstumorproliferativecapacityandpatientssurvival AT damaskoschristos histonedeacetylasehdac124and6expressioninhumanpancreaticadenocarcinomaassociationswithclinicopathologicalparameterstumorproliferativecapacityandpatientssurvival AT koutsounasioannis histonedeacetylasehdac124and6expressioninhumanpancreaticadenocarcinomaassociationswithclinicopathologicalparameterstumorproliferativecapacityandpatientssurvival AT ziziserbetzoglouadamantia histonedeacetylasehdac124and6expressioninhumanpancreaticadenocarcinomaassociationswithclinicopathologicalparameterstumorproliferativecapacityandpatientssurvival AT tsoukalasnicolaos histonedeacetylasehdac124and6expressioninhumanpancreaticadenocarcinomaassociationswithclinicopathologicalparameterstumorproliferativecapacityandpatientssurvival AT patsourisefstratios histonedeacetylasehdac124and6expressioninhumanpancreaticadenocarcinomaassociationswithclinicopathologicalparameterstumorproliferativecapacityandpatientssurvival AT kouraklisgregorios histonedeacetylasehdac124and6expressioninhumanpancreaticadenocarcinomaassociationswithclinicopathologicalparameterstumorproliferativecapacityandpatientssurvival AT theocharisstamatios histonedeacetylasehdac124and6expressioninhumanpancreaticadenocarcinomaassociationswithclinicopathologicalparameterstumorproliferativecapacityandpatientssurvival |